Planegg – Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at the following upcoming conferences:
Kempen Life Sciences Conference
Date: 18 – 19 April 2018
Location: Amsterdam, Netherlands
16th CIMT Annual Meeting
Date: 15 – 17 May 2018
Location: Mainz, Germany
The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Date: 16 – 19 May 2018
Location: Chicago, USA
UBS Global Life Science Conference
Date: 21 – 23 May 2018
Location: New York, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation on 22 May.
3rd Annual Advances in Immuno-Oncology Congress
Date: 24 – 25 May 2018
Locations: London, UK
Prof. Dolores Schendel, CEO and CSO of Medigene AG, will present on “T cell receptor discovery to match medical needs worldwide” on May 24.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,